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1. Introduction 
Tuberculosis (TB) is an infectious disease, caused by an 
extremely slow growing bacterial pathogen belonging to the 
Mycobacterium tuberculosis complex.1 Among them, M. 
tuberculosis is responsible for the majority of human deaths.2 It is 
estimated that at least one-third of the world's population is 
latently infected with the bacteria that causes TB, while in 2012, 
WHO reported 8.6 million new cases of the disease and 1.3 
million deaths due to it, worldwide.3 Lengthy treatment regimens 
have as a consequence, the rise of drug resistant TB-causing 
strains. This has set the alarm for controlling the disease, which 
necessitates the discovery of new therapeutic targets and 
synthesis of novel inhibitors.  
In order to specifically inhibit mycobacterial growth, 
alternative metabolic pathways, exclusive to the bacteria, need to 
be targeted for an efficient anti-TB drug development 
programme.4 In this regard, we focused our interest on the 
genome of M. tuberculosis, which has been reported to contain a 
thyX gene (Rv2754c), encoding the ThyX protein, a flavin-
dependent thymidylate synthase responsible for the de novo 
synthesis of 2’ –deoxythymidine 5’-monophosphate (dTMP), a 
key precursor of DNA.5  ThyX, present primarily in prokaryotes 
and viruses, is rare in eukaryotes and absent in humans, where 
the corresponding metabolic function is carried out by the 
conventional ThyA protein. Both the enzymes catalyze the 
reductive methylation of 2’-deoxy-uridine-5’–monophosphate 
(dUMP) to dTMP in the presence of methylenetetrahydrofolate; 
however, based on their structural and catalytic dissimilarities, 
different enzymatic mechanisms have been suggested for each.6 
In contrast to ThyA, where methylenetetrahydrofolate acts both 
as the carbon donor and reducing agent, ThyX uses 
methylenetetrahydrofolate as the one-carbon donor molecule and 
reduced flavin adenine dinucleotide (FADH2) as a cofactor that 
serves as the hydride donor.7  
Micro-organisms contain either ThyA or ThyX; however, 
mycobacteria encode both ThyA and ThyX. However, a 
sequence similarity search yielded no significant matches 
between ThyX of mycobacteria to the ThyA of other eukaryotic 
cells. Recently, functional studies, devoted to investigate the 
biological role of both of these enzymes, showed that ThyX is 
essential for the survival of M. tuberculosis even in the presence 
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of ThyA and exogenous thymidine.8,9 M. tuberculosis cannot 
utilize exogenous thymidine sources because it lacks thymidine 
kinase, the essential enzyme for the conversion of thymidine into 
dTMP.5 All these factors support the existence of ThyX enzyme 
as a prospective therapeutic target for the development of a new 
selective anti-tubercular drug treatment.10 
The chemical class of C5-alkynyl substituted 2’-deoxyuridine-
5’-monophosphate (dUMP) has been reported as selective 
inhibitor of ThyX in M. tuberculosis.11 In this study, among 
several compounds, N–(3-(5-(2’-deoxyuridine-5’-
monophosphate))prop-2-ynyl)octanamide 1 (figure 1) was 
identified as the most potent and selective analogue with an IC50 
value of 0.91 M versus recombinant ThyX from M. 
tuberculosis. However, the polarity of this compound constitutes 
a major obstacle for its penetration through the complex 
mycobacterial cell wall. Indeed one of the major challenges for 
chemotherapeutic drugs is associated with difficulties in crossing 
the thick, lipid-rich cell wall of the mycobacteria, which prevents 
their permeation, with a consequential poor biological response. 
In particular, the permeation of hydrophilic compounds is not 
very efficient due to the presence of low numbers and the 
exceptional length of porins, water-filled open channels, 
responsible for mediating the diffusion of hydrophilic nutrients.12 
Moreover, the existence of active drug efflux pumps reduces the 
concentration of active molecules inside the bacterial cell and 
their up-regulation has been suggested to contribute to the 
emergence of drug resistance.13 To the contrary more lipophilic 
drugs are more likely to diffuse through the lipid-rich 
environment of the mycobacterial cell wall. In addition to high 
polarity, the instability of 1 in biological media, a well-known 
drawback for free nucleoside phosphates, may also limit its 
therapeutic potential, with dephosphorylation likely exceeding 
cell permeation. 
To improve stability, permeability and therefore antibacterial 
activity, lipophilic prodrugs of 1 are thus required. Among 
several strategies developed to overcome these issues, our 
phosphoramidate ProTide approach was selected for this 
study.14,15 This technology consists of masking the negative 
charges of the phosphate group with an aromatic moiety and an 
amino acid ester. To date, this approach has been widely applied 
mainly to antiviral16 and anticancer nucleoside analogues17 and 
more recently also to N-acetyl glucosamine to treat 
osteoarthritis.18 Typically, two enzymatic cleavages are involved 
in the cellular bio-activation of antiviral and anticancer ProTides, 
either in the viral infected or human cancer cell.19 Firstly, a 
carboxypeptidase-type enzyme may mediate the cleavage of the 
ester moiety. This step is followed by a spontaneous intra-
molecular cyclisation with the subsequent release of the aryl 
moiety and formation of an unstable mixed cyclic anhydride 
which undergoes ring-opening mediated by water to release a 
mono ester phosphate prodrug. In the last step, a 
phosphoramidase-type enzyme, most probably a human Hint-1, 
may be responsible for the cleavage of the phosphorus-nitrogen 
bond with the consequent release of the monophosphate. 
Since we wanted to investigate whether phosphoramidates of 
1 are capable of crossing the cell wall of mycobacteria and to be 
bio-converted into the monophosphate once inside, herein we 
report the synthesis of several derivatives and their biological 
evaluation against the TB vaccine strain, M. bovis BCG and the 
virulent TB causing lab strain, M. tuberculosis H37Rv, using HT-
SPOTi, a rapid but gold standard whole-cell phenotypic assay. 
This is the first time that the application of the ProTide 
technology has been reported for improving the antimicrobial 
activity of inhibitors of a protein target of M. tuberculosis. 
 
 
 
 
 
 
 
Figure 1. N-(3-(5-(2’-deoxyuridine-5’-monophosphate))prop-2-
ynyl)octanamide 1. 
The Prodrugs were prepared by chemical modification of 
nucleoside 2 rather than directly modifying compound 1 (see 
Scheme 1). As ThyX proteins are also found in several double-
stranded DNA viruses5 and considering that some 5-alkynyl-2′-
deoxyuridine analogues, in addition to their anti-TB activity20-22 
showed significant antiviral activity23 we also report the antiviral 
evaluation of the parent nucleoside of 2 and its prodrug 
monophosphate derivatives.  
2. Results and Discussion  
2.1. Chemistry  
The phosphoramidates 7a–l described in this study are 
shown in Table 1 with the reaction sequence for their synthesis 
summarized in Scheme 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthetic method to obtain compounds 7a-l. 
Reagents and Conditions: (a) Octanoyl chloride, DIPEA, 
anhydrous CH2Cl2, 0°C to 20°C, 2h; (b) Propargyloctanamide 
(3), Pd(Ph3)4, CuI, DIPEA, anhydrous DMF, 20°C ; (c) 
Phosphorochlorides 6a-l (for R, R’, R’’ and R’’’ see table 1), 
NMI, anhydrous THF, 20°C, 12h. 
 
Our synthetic efforts started with the synthesis of the 
propargyloctylamide 4 from propargylamine 3 and octanoyl 
chloride.11 Then, Sonogashira cross coupling24 of the 
commercially available 5-iodo-2’-deoxyuridine 5 with alkyne 4 
afforded the desired nucleoside 2, isolated in excellent yield 
(91%) without column chromatography purification. It is 
noteworthy to mention that our synthetic procedure to the 
preparation of 2 was made less time-consuming than the 
previously reported procedure, with great improvement in terms 
of yield achieved.11 Following the general synthetic procedure for 
compounds 7a-l, nucleoside 2 was reacted with the appropriate 
phosphorochloridate 6a-l using N-methylimidazole as activator, 
according to a previously described method.25 The desired 
phosphoroamidates 7a-l were obtained from 5 to 39% yield. 
Yield optimization was beyond the scope of the work as we were 
in the early stages of establishing biological activity and potential 
lead molecules.
 
Table 1 
Substituent pattern, yields and 31P NMR shifts of phosphoramidates 7a-l.  
Cpds R R’ R’’ AA R’’’ Yield (%) 31P NMR (ppm) a 
7a Naph H CH3 (L)-Ala CH3 20 4.36; 4.07 
7b Naph H CH3 (L)-Ala CH2CH3 5 4.36; 4.09 
7c Naph H CH3 (L)-Ala CH2CH( CH3)2 39 4.34; 4.07 
7d Naph H CH3 (L)-Ala CH2Ph 14 4.36; 3.98 
7e Ph H CH3 (L)-Ala CH3 16 3.98; 3.57 
7f Ph H CH3 (L)-Ala CH2CH3 29 3.99; 3.58 
7g Ph H CH3 (L)-Ala (CH2)2CH3 12 4.00; 3.59 
7h Ph H CH3 (L)-Ala CH2Ph 12 4.01; 3.51 
7i Ph CH3 H (D)-Ala CH2Ph 16 3.98; 3.50 
7j Ph H H Gly CH2Ph 29 5.02; 4.93 
7k Ph CH3 CH3 DMG CH2Ph 9 2.39; 2.10 
7l Ph H CH(CH3)2 (L)-Val CH2Ph 14 4.95; 4.30 
a Recorded at 202 MHz in MeOH-d4 with 85% H3PO4 as reference
2.2. Biological activities  
2.2.1 Antimycobacterial specificity 
All synthesized compounds 7a-l and nucleoside 2 were evaluated 
in vitro against M. bovis BCG and, M. tuberculosis H37Rv using 
the HT-SPOTi assay26 at 1-250 mg/L concentrations. This whole-
cell assay was indicative toward inherent resistance, such as cell 
wall impermeability. In order to evaluate a specific endogenous 
mechanism of anti-mycobacterial action for these compounds via 
ThyX inhibition, we also tested their biological activity against 
E. coli, a Gram-ve bacterium where a functional ThyX 
homologue is missing from the genome. The minimum inhibitory 
concentrations (MIC) of compounds that completely inhibited 
growth of both mycobacterial strains are shown in Table 2.   
The highly hydrophilic nucleoside 2 (ClogP = -0.21) did not 
exhibit antimycobacterial activity with a MIC> 250 mg/L (Table 
2). For the first series of phosphoroamidates bearing a naphthyl 
group as an aromatic part (7a-d), a structure-activity relationship 
(SAR) was found with the activity depending on the size of the 
ester group of the L-alanine amino acid moiety. Methyl and ethyl 
derivatives (7a ClogP = 1.89; 7b ClogP = 2.42) showed better 
inhibitory activity (7a MIC = 62.5 mg/L; 7b MIC = 125 mg/L), 
whereas more hindered and lipophilic benzyl analogue (7d ClogP 
= 3.60) was found to be significantly less inhibitory (MIC = 250 
mg/L). A possible reason for this ﬁnding could be due to the 
higher size of compound 7d that may prevent its entry inside the 
bacteria. 
The second series of compounds bearing a phenyl aromatic 
moiety (7e-l) showed a different SAR. The smallest alkyl esters 
(7e ClogP = 0.71; 7f ClogP = 1.24) did not inhibit mycobacteria 
growth, while propyl and benzyl derivatives (7g ClogP = 1.77; 
7h ClogP= 2.43) were slightly active (MIC = 125 mg/L). Further 
investigation on the amino acid part highlighted a certain 
preference toward alanine with the D-alanine analogue (7i) 
showing a MIC of 62.5 mg/L.  
Table 2  
Antimycobacterial specificity of nucleoside 2 and 
phosphoroamidates 7a-l. 
a Clog P values were calculated using CambridgeSoft ChemDraw® 
software. MICBCG and MICH37Rv state the minimum inhibitory concentration 
Cpds Clog Pa MICBCG(mg/L) MICH37Rv(mg/L) 
2 -0.21 >250 >250 
7a 1.89 62.5 62.5 
7b 2.42 125 125 
7c 3.74 125 62.5 
7d 3.6 250 250 
7e 0.71 >250 >250 
7f 1.24 250 250 
7g 1.77 125 125 
7h 2.43 125 125 
7i 2.43 62.5 125 
7j 2.31 >250 >250 
7k 2.73 125 >125 
7l 3.35 125 31.25 
of the compounds tested against M. bovis BCG and M. tuberculosis H37Rv 
respectively.   
 
Glycine derivative 7j, showed no activity against M. bovis 
BCG, whereas dimethylglycine or L-valyl derivatives (7k and 7l) 
in the same assay were slightly active. (MIC = 125 mg/L). 
However, results for 7i and 7l differed in the case of M. 
tuberculosis H37Rv as can be inferred from the table.  
Therefore, we postulate that the bioactivity against M. bovis 
BCG and M. tuberculosis H37Rv of phosphoroamidates 7a, 7b, 
7c, 7g, 7h, 7i and 7l might result from better permeation through 
the mycobacterial cell wall due to an improved balance between 
their lipophilicity and molecular size. Potencies are moderate in 
this first series of compounds and subsequent work is required to 
optimize their biological activity; however, there is a clear 
antimycobacterial effect for some of these molecules. Notably, 
the parent nucleoside 2 was devoid of activity showing the 
crucial importance of the ProTide motif. 
No homologues with significant sequence similarity with the 
protein ThyX of M. tuberculosis were found in E. coli. This 
could be a possible explanation for the inactivity of the 
compounds towards this organism.  
 
2.2.2 Antiviral Activity 
Parent nucleoside 2 and all synthesized phosphoramidates 
were also evaluated for their antiviral activity against varicella 
zoster virus (VZV), herpes simplex virus type 1 (HSV-1) and 2 
(HSV-2), and human cytomegalovirus (HCMV), vaccinia virus 
(VV) according to previously described methods.27 
Phosphoroamidate 7h exhibited anti-VZV and anti-HSV 
activities in the low micromolar range (Table 3). 
However, although quite potent against a thymidine kinase 
positive (TK+) strain of VZV, 7h was not active versus the 
thymidine kinase-deficient (TK-) strain. This showed the 
importance of this enzyme in the bioactivation of this class of 
molecules to its active species. Moreover, the lead compound, the 
L-alanine benzyloxy ester phosphoramidate with a phenyl 
aromatic group 7h, presented similar activity (EC50 = 2.0 μM) to 
acyclovir (EC50 = 2.6 μM) against VZV. 7h was also found to be 
active against HSV-1 and HSV-2 (EC50 of 2 and 4 μM) but not 
against a TK- strain of HSV-1. In the case of 7a, 7c, 7d, the 
antiviral activity observed against VZV may be rather due to 
their underlying cytotoxicity. The compounds were not active 
against HCMV and VV (data not shown) in HEL cell cultures.
 
Table 3 
Antiviral activity and cytotoxicity of phosphoramidates 7a, 7c, 7d and 7h. 
 
Compounds 
EC50a (μM) 
CC50b 
(μM) 
MCCc 
(μM) 
VZV HSV-1 HSV-2 
TK+ OKA TK- 07-1 TK+ 
KOS 
TK-KOS G 
2 >100 >100 >100 >100 >100 >100 - 
7a 37 46 >100 >100 >100 64 >100 
7c 20 >20 >100 >100 >100 15 >100 
7d 8.6 >20 >100 >100 >100 39 >100 
7h 2.0 >20 2 >100 4 48 >100 
acyclovir 2.6 140 0.2 50 0.1 440 >440 
aEffective concentration required to reduce virus plaque formation by 50%. VZV, HSV-1 and HSV-2 represent EC50 values for varicella zoster virus, herpes 
simplex virus strains respectively. bCytotoxic concentration required to reduce cell growth by 50%. cMinimum cytotoxic concentration that causes a 
microscopically detectable alteration of cell morphology. 
 
3. Conclusion 
A phosphoroamidate prodrug (ProTide) approach was used to 
seek to deliver the pre-formed bioactive monophosphate of a new 
compound recently reported to be a potent and selective inhibitor 
of thymidylate synthase X, an enzyme essential for the survival 
of M. tuberculosis. The lipophilic ProTide motif was designed to 
improve permeability trough the mycobacterial cell wall. We 
have successfully synthesized twelve phosphoroamidate 
derivatives of N–(3-(5-(2’-deoxyuridine-5’-
monophosphate))prop-2-ynyl)octanamide 1, a potent in vitro 
ThyX inhibitors. Biological tests of our prodrugs showed 
antimycobacterial activity against M. tuberculosis H37Rv and M. 
bovis BCG in contrast to inactivity from the parent nucleoside. 
We considered that the increased lipophilicity together with the 
correct molecular size of phosphoroamidate derivatives 7a, 7b, 
7c 7g, 7h 7i and 7l allowed them to penetrate through the 
mycobacterial cell wall liberating the monophosphate 
intracellulary and targeting their proposed biological target, 
ThyX protein. 
Moreover, we found interesting activities against VZV for 
some of our compounds, showing the necessity of the pro-moiety 
to help transport of the drug into cells. We identified the L-
alanine benzyl ester phosphoramidate with the phenyl aromatic 
group 7h as a potent antiviral agent, showing similar activity to 
acyclovir against VZV in this assay.  
The results obtained highlight the possibility that the ProTide 
methodology could be used for the development of active 
molecules against TB and reveal the importance of improving 
lipophilicity to efficiently pass the mycobacteria wall barrier. To 
the best of our knowledge this is the first application of the 
ProTide technology to anti-mycobacterial agents. Further work is 
currently underway to enhance the potency of the new agents we 
herein report for the first time.  
4. Experimental  
4.1 Synthesis 
Solvents and Reagents. The following anhydrous solvents 
were purchased from Sigma-Aldrich: dichloromethane (CH2Cl2), 
tetrahydrofuran (THF), dimethylformamide (DMF), and any 
other reagents used. Amino acid esters commercially available 
were purchased from Novabiochem. All reagents commercially 
available were used without further purification. Propargylamide 
and octanoyl chloride were purchased from Aldrich whereas 5-
iodo-2’-deoxyuridine from Berry & Associates.  
Thin Layer Chromatography (TLC). Precoated aluminum 
backed plates (60 F254, 0.2 mm thickness, Merck) were 
visualized under both short and long wave ultraviolet light (254 
and 366 nm) or by burning using the following TLC indicators: 
(i) molybdate ammonium cerium sulfate; (ii) potassium 
permanganate solution. Preparative TLC plates (20 cm × 20 cm, 
500-2000 μm) were purchased from Merck. 
Flash Column Chromatography. Flash column 
chromatography was carried out using silica gel supplied by 
Fisher (60A, 35-70 μm). Glass columns were slurry packed using 
the appropriate eluent with the sample being loaded as a 
concentrated solution in the same eluent or preadsorbed onto 
silica gel. Fractions containing the product were identified by 
TLC, and pooled and the solvent was removed in vacuo. 
High Performance Liquid Chromatography (HPLC). The 
purity of the final compounds was verified to be >95% by HPLC 
analysis using either I) ThermoSCIENTIFIC, SPECTRA 
SYSTEM P4000, detector SPECTRA SYSTEM UV2000, Varian 
Pursuit XRs 5 C18, 150 x 4.6 mm (as an analytic column) or II) 
Varian Prostar (LC Workstation-Varian Prostar 335 LC detector), 
Thermo SCIENTIFIC Hypersil Gold C18, 5, 150 x 4.6 mm (as 
an analytic column). For the method of elution see the 
experimental part.  
Nuclear Magnetic Resonance (NMR). 1H NMR (500 MHz), 
13C NMR (125 MHz) and 31P NMR (202 MHz) were recorded on 
a Bruker Avance 500 MHz spectrometer at 25 ºC. Chemical 
shifts (δ) are quoted in parts per million (ppm) relative to internal 
MeOH-d4 (δ 3.34 1H NMR, δ 49.86 13C NMR) and CHCl3-d (δ 
7.26 1H NMR, δ 77.36 13C NMR) or external 85 % H3PO4 (δ 0.00 
31P NMR). Coupling constants (J) are measured in Hertz. The 
following abbreviations are used in the assignment of NMR 
signals: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), bs (broad singlet), dd (doublet of doublet), dt 
(doublet of triplet), app (apparent). The assignment of the signals 
in 1H NMR and 13C NMR was done based on the analysis of 
coupling constants and additional two-dimensional experiments 
(COSY, HSQC, HMBC, PENDANT).  
Mass spectrometry (MS). Low resolution mass spectra were 
performed on Bruker Daltonics microTof-LC, (atmospheric 
pressure ionization, electron spray mass spectroscopy) in positive 
mode.  
 
4.1.1. Synthesis of N–(3-(5-(2’-deoxyuridine))prop-2-
ynyl)octanamide 2 
Propargyloctanamide (4). Propargylamine 3 (2.5 mL, 45.38 
mmol) was dissolved in anhydrous CH2Cl2 (113 mL) DIPEA 
(10.4 mL, 59.46 mmol) was added and the solution was cooled to 
0 oC. Octanoyl chloride (8.52 mL, 49.92 mmol) was added 
dropwise and the reaction mixture was stirred at room 
temperature for 2 h. The reaction was quenched through 
dropwise addition of H2O (5 mL) then diluted with CH2Cl2 and 
washed with saturated solution of NaHCO3 and brine, dried over 
MgSO4 and evaporated to obtain 4 as an orange solid (99%, 8.3 
g) which was used in the subsequent Sonogashira-coupling step 
without further purification. 1H NMR (500 MHz, CHCl3- d): H 
5.68 (brs, 1H, NH) 4.04 (dd, 2H, J = 7.5 and 2.5 Hz, CH2C≡C), 
2.22 (t, 1H, J = 2.8 Hz, HC≡C), 2.20 (t, 2H, J = 8.0 Hz, CH2CO), 
1.69-1.61 (m, 2H, CH2CH2CO), 1.31-1.28 (m, 8H, 4 x CH2), 0.88 
(t, 3H, J = 6.8 Hz, CH3). 
 
4.1.2. N–(3-(5-(2’-deoxyuridine))prop-2-ynyl)octanamide 
(2). A solution of 5-iodo-2’-deoxyuridine 5 (4.00 g, 11.29 mmol), 
alkyne 4 (6.14 g, 33.89 mmol), tetrakis Pd(PPh3)4 (1.30 g, 1.13 
mmol), Cu(I)I (0.43 g, 2.26 mmol) and anhydrous DIPEA (3.93 
mL, 22.58 mmol) in anhydrous DMF (75 mL) was stirred under 
an argon atmosphere at room temperature overnight. After this 
period, the solvent was removed under reduced pressure and the 
residue was suspended in CH2Cl2 and stirred at room temperature 
for 2 h. The suspension was filtered and the solid was washed 
with CH2Cl2 to give the desired compound as a light brown solid 
(91%, 4.20 g). For biological testing, the compound 2 was 
purified by preparative TLC using CH2Cl2/MeOH 9/1 as eluent.  
1H NMR (500 MHz, DMSO-d6): H 11.59 (s, 1H, NH), 8.26 (t, 
1H, J = 5.4 Hz, NH amide), 8.15 (s, 1H, H-6), 6.12 (t, 1H, J = 6.7 
Hz, H-1’), 5.23 (d, 1H, J = 4.3 Hz, 3’-OH), 5.07 (t, 1H, J = 5.0 
Hz, 5’-OH), 4.25-4.22 (m, 1H, H-3’), 4.06 (d, 2H, J = 5.5 Hz, 
NHCH2), 3.80 (q, 1H, J = 3.3 Hz, H-4’), 3.62-3.56 (m, 2H, H-5’), 
2.13-2.07 (m, 4H, H-2’, COCH2), 1.52-1.46 (m, 2H, 
COCH2CH2), 1.28-1.21 (m, 8H, 4 x CH2), 0.86 (t, 3H, J = 6.9 Hz, 
CH3). 13C (125 MHz, DMSO-d6): C 171.83 (CONH), 161.57 (C-
4), 149.39 (C-2), 143.57 (C-6), 98.14 (C-5), 89.76 (CH2C≡C), 
87.61 (C-4’), 84.69 (C-1’), 74.18 (CH2C≡C), 70.23 (C-3’), 61.02 
(C-5’), 40.06 (C-2’), 35.06 (COCH2), 31.12, 28.58, 28.47, 28.39, 
25.09, 22.01 (6 x CH2), 13.89 (CH2CH3). MS (ES-) m/z 442 
(M+Cl-, 100%), 406 (M-H+, 39%). Reverse-phase HPLC, eluting 
with H2O/MeOH from 90/10 to 0/100 in 40 min, Flow = 1 
mL/min,  = 280 nm, tR= 25.71 min  
 
4.1.3. Synthesis of phosphoramidates 7a-l. General 
procedure. To a solution of nucleoside 5 (1 mol/eq) and the 
appropriate phosphorochloridate 6a-l (3-5 mol/eq) in anhydrous 
THF, anhydrous NMI (5 mol/eq) was added dropwise and the 
reaction mixture was stirred at room temperature overnight. After 
this period, the solvent was removed under reduced pressure and 
the residue dissolved in CH2Cl2. The organic phase was washed 
with 0.5 M aqueous solution of citric acid, water and brine. The 
organic phase was dried over MgSO4, filtered and concentrated. 
The crude was purified by column chromatography using 
different eluting systems. Some of the compounds were further 
purified by preparative TLC using different eluting systems. All 
the compounds were recovered as a mixture of RP and Sp 
diastereoisomers. 
 
4.1.3.1 N-{3-[5-(2’-Deoxy-5’-O-(1-naphthyl(methyloxy-L-
alaninyl)phosphate-uridine))] prop-2-ynyl)octanamide (7a). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and naphthyl(methyloxy-L-
alaninyl)phosphorochloridate 6a (0.80 g, 2.45 mmol) in 
anhydrous THF (20 mL) and anhydrous NMI (0.19 mL, 2.45 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
from 98/2 to 95/5. The residue was further purified by 
preparative TLC eluting with CH2Cl2/MeOH  95/5 to give 7a as a 
white solid (20%, 0.07 g). 1H NMR (500 MHz, MeOH-d4): H 
8.19 (d J = 7.5 Hz, 1H, Naph), 7.95 (s, 0.5H of one 
diastereoisomer, H-6), 7.93 (s, 0.5H of one diastereoisomer, H-
6), 7.92-7.89 (m, 1H, Naph), 7.84 (d, J = 7.5 Hz, 0.5H of one 
diastereoisomer, Naph), 7.74 (d, J = 7.5 Hz, 0.5H of one 
diastereoisomer, Naph), 7.60-7.53 (m, 3H, Naph), 7.47-7.43 (m, 
1H, Naph), 6.17 (t, J = 5.5 Hz, 0.5H of one diastereoisomer H-
1’), 6.15 (t, J = 6.0 Hz, 0.5H of one diastereoisomer H-1’), 4.44-
4.33 (m, 3H, H-3’, H-5’), 4.16-4.07 (m, 2H, H-4’ and CHCH3), 
3.97, 3.96, 3.93 (3s, 2H, NHCH2C≡), 3.68, 3.67 (s, 3H, OCH3), 
2.22 (ddd, J = 14.0, 6.5 and 3.0 Hz, 0.5H of one diastereoisomer, 
H-2’), 2.16 (ddd, J = 14.0, 6.0 and 3.0 Hz, 0.5H of one 
diastereoisomer, H-2’), 2.13 (t, J = 7.5 Hz, 1H, COCH2CH2), 
2.09 (t, J = 7.5 Hz, 1H, COCH2CH2), 1.89-1.83 (m, 0.5H of one 
diastereoisomer, H-2’), 1.80-1.76 (m, 0.5 H of one 
diastereoisomer, H-2’) 1.57-.151 (m, 2H, COCH2CH2-), 1.39 (d, 
J = 8.5 Hz, 1.5H of one diastereoisomer, CHCH3), 1.38 (d, J = 
8.5 Hz, 1.5H of one diastereoisomer, CHCH3), 1.31-1.21 (m, 8H, 
4 x CH2), 0.89 (t J = 7.0 Hz, 3H, CH3). 13C (125 MHz, MeOH-
d4): C 175.71, 175.68 (CONH), 175.23 (d, 3JC-P= 4.6 Hz, 
COOCH3), 175.10 (d, 3JC-P= 3.7 Hz, COOCH3), 164.46 (C-4), 
151.96, 15141 (C-2), 148.04 (d, 2JC-P = 8.0 Hz, ‘ipso’ PhO), 
144.59 (C-6), 136.32, 137.30, 128.98, 128.95, 127.92, 127.72, 
127.62, 126.63, 126.56, 126.25, 126.19, 122.72, 122.66 (C-1 
‘ipso’ Naph, C-3 Naph, C-4 Naph, C-4a Naph, C-5 Naph, C-6 
Naph, C-7 Naph, C-8 Naph, C-8a Naph), 116.47 (d, 3JC-P = 2.9 
Hz, C-2 Naph), 116.41 (d, 3JC-P = 3.4 Hz, C-2 Naph), 100.26 (C-
5), 90.36, 90.32 (CH2C≡C), 87.44, 87.36 (C-1’), 87.16 (d, 3JC-P = 
8.2 Hz, C-4’), 86.95 (d, 3JC-P = 8.2 Hz, C-4’), 75.42, 75.37 
(CH2C≡C), 72.24, 72.13 (C-3’), 67.85 (d, 2JC-P = 5.5 Hz, C-5’), 
52.85 (OCH3), 51,80, 51.69 (CHCH3), 41.34, 41.27 (C-2’), 36.90, 
36.87 (COCH2), 32.91, 30.54, 30.48, 30.26, 30.13, 26.84, 26.82, 
23.67 (CH2NHCO, 6 x CH2), 20.59 (d, 3JC-P = 6.1 Hz, CHCH3), 
20.45 (d, 3JC-P = 7.2 Hz, CHCH3), 14.42 (CH3).31P NMR (202 
MHz, MeOH-d4): P 4.36, 4.07. MS (ES+) m/z: 721 (M+Na+, 
100%). Reverse-phase HPLC, eluting with H2O/ACN from 90/10 
to 0/100 in 30 min, Flow = 1mL/min,  = 280 nm, tR= 17.86 min.  
 
4.1.3.2 N-{3-[5-(2’-Deoxy-5’-O-(1-naphthyl(ethyloxy-L-
alaninyl)phosphate-uridine))]prop-2-ynyl)octanamide (7b). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and naphthyl(ethyloxy-L-
alaninyl)phosphorochloridate 6b (0.84 g, 2.45 mmol) in 
anhydrous THF (15 mL) and anhydrous NMI (0.19 mL, 2.45 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of ethyl 
acetate/MeOH = 100/0 to 98/2. The residue was further purified 
by preparative TLC eluting with CH2Cl2/MeOH 95/5 to give 7b 
as a white solid (5%, 0.02 g). 1H-NMR (500 MHz; MeOH-d4): H 8.20-7.42 (m, 8H, Naph, H-6), 6.17-6.14 (m, 1H, H-1’), 4.45-
4.32 (m, 3H, H-3’, H-5’), 4.17-4.07 (m, 4H, H-4’, COOCH2CH3, 
CHCH3), 3.97, 3.93, 3.91 (3s, 2H, NHCH2C≡C), 2.23-2.17 (m, 
1H, H-2’), 2.16-2.08 (m, 2H, COCH2CH2), 1.87-1.74 (m, 1H, H-2’), 1.58-1.51 (m, 2H, COCH2CH2), 1.43-1.21 (m, 14H, 4 x CH2, 
COOCH2CH3, CHCH3), 0.89-0.84 (t, 3H, J = 6.7 Hz, 
CH2CH2CH3). 13C NMR (125 MHz, MeOH-d4): C 175.69, 
175.68 (CH2CO), 175.05, 174.73 (COOCH2CH3), 164.36 (C-4), 
151.05, 150.93 (C-2), 148.00 (d, 2JC-P = 7.4 Hz, C-1 ‘ipso’ Naph), 
147.97 (d, 2JC-P = 7.2 Hz, C-1 ‘ipso’ Naph), 144.55 (C-6), 136.29, 
136.28, 128.95, 128.92, 127.91, 127.90, 127.84, 127.68, 127.58, 
126.61, 126.60, 126.53, 126.52, 126.22, 126.17, 126.53, 126.52 
(C-3 Naph, C-4 Naph, C-4a Naph, C-5 Naph, C-6 Naph, C-7 
Naph, C-8 Naph, C-8a Naph), 116.42 (d, 3JC-P = 3.4 Hz, C-2 
Naph), 116.37 (d, 3JC-P = 3.2 Hz, C-2 Naph), 100.24 (C-5), 90.33 
(CH2C≡C), 87.40, 87.37 (C-1’), 87.15 (d, 3JC-P = 8.4 Hz, C-4’), 
86.91 (d, 3JC-P = 8.1 Hz, C-4’), 75.40 (CH2C≡C), 72.22, 72.11 (C-3’), 67.86 (d, 2JC-P = 5.4 Hz, C-5’), 62.47 (COOCH2CH3), 51.87, 
51.77 (CHCH3), 41.33, 41.25 (C-2’), 36.87, 36.84 (COCH2), 
32.85, 30.53, 30.44, 30.23, 30.09, 26.80, 23.64 (CH2NHCO, 6 x 
CH2), 20.61 (d, 3JC-P = 6.6 Hz, CHCH3), 20.47 (d, 3JC-P = 7.7 Hz, 
CHCH3), 14.46, 14.39 (COOCH2CH3, CH3). 31P-NMR (202 
MHz; MeOD-d4): δP 4.36, 4.09. MS (ES+) m/z: 735 (M+Na+, 
100%). Reverse-phase HPLC, eluting with H2O/ MeOH from 
90/10 to 0/100 in 40 min, Flow = 1 mL/min,  = 280 nm, tR= 
34.49 min (99.05%).  
 
4.1.3.3 N-{3-[5-(2’-Deoxy-5’-O-(1-naphthyl(neopentyloxy-L-
alaninyl)phosphate-uridine))] prop-2-ynyl)octanamide (7c). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and naphthyl(neopentyloxy-L-
alaninyl)phosphorochloridate 6c (0.94 g, 2.45 mmol) in 
anhydrous THF (20 mL) and anhydrous NMI (0.19 mL, 2.45 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
from 98/2 to 95/5. The residue was further purified by 
preparative TLC eluting with CH2Cl2/MeOH = 95/5 to give 7c as 
a white solid (39%, 0.13 g). 1H NMR (500 MHz, MeOH-d4): H 
8.22-8.18 (m, 1H, Naph), 7.93 (s, 0.65H of one diastereoisomer, 
H-6), 7.92 (s, 0.35H of one diastereoisomer, H-6), 7.90-7.88 (m, 
1H, Naph), 7.72 (d J = 8.5 Hz, 0.35H of one diastereoisomer, 
Naph) 7.71 (d, J = 8.5 Hz, 0.65H of one diastereoisomer, Naph) 
7.58-7.52 (m, 3H, Naph), 7.46-7.42 (m, 1H, Naph), 6.16-6.12 (m, 
1H, H-1’), 4.45-4.32 (m, 3H, H-3’, H-5’), 4.16-4.07 (m, 2H, H-
4’, CHCH3), 3.99, 3.97, 3.95, 3.94 (4s, 2H, NHCH2C≡), 3.87, 
3.86, 3.76, 3.75 (2x AB, 4H, JAB = 10.5 Hz, 2x OCH2C(CH3)3), 
2.21-2.14 (m, 1H, H-2’), 2.13 (t, J = 7.5 Hz, 1H, COCH2CH2), 
2.08 (t, J = 7.5 Hz, 1H, COCH2CH2), 1.83-1.73 (m, 1H, H-2’), 
1.56-1.51 (m, 2H, COCH2CH2), 1.43 (d, J = 7.0 Hz, 3H, 
CHCH3), 1.29-1.19 (m, 8H, 4 x CH2), 0.94, 0.93 (2s, 9H, 
OCH2C(CH3)3), 0.87 (t, J = 6.5 Hz, 3H, CH3). 13C (125 MHz, 
MeOH-d4): C 175.68, 175.64 (CONH), 175.16 (d, 3JC-P= 5.0 Hz, 
CO2CH2C(CH3)3), 174.83 (d, 3JC-P= 4.7 Hz, CO2CH2C(CH3)3), 
164.42 (C-4), 151.00, 150.97 (C-2), 148.00 (d, 2JC-P = 7.3 Hz,  C-1 ‘ipso’ Naph), 147.90 (d 2JC-P = 7.2 Hz, C-1 ‘ipso’ Naph), 
144.64, 144.60 (C-6), 136.32, 136.30, 128.99, 128.97, 127.93, 
127.73, 127.63, 126.67, 126.58, 126.28, 126.21, 122.77, 122.69 
(C-3 Naph, C-4 Naph, C-4a Naph, C-5 Naph, C-6 Naph, C-7 
Naph, C-8 Naph, C-8a Naph), 116.48 (d, 3JC-P = 5.7 Hz, C-2 
Naph), 100.30, 100.27 (C-5), 90.36, 90.33 (CH2C≡C), 87.43, 
87.41 (C-1’), 87.19, (d, 3JC-P = 8.5 Hz, C-4’), 86.95 (d, 3JC-P = 8.1 
Hz, C-4’),  75.55 (OCH2C(CH3)3), 75.10 (CH2C≡C),  72.30, 
72.14 (C-3’), 67.97 (d, 2JC-P = 5.0 Hz, C-5’), 67.92 (d, 2JC-P = 5.0 
Hz, C-5’), 52.03, 51.89 (CHCH3), 41.36, 41.31 (C-2’), 36.94, 
36.89 (COCH2), 32.90 (CH2), 32.39 (C(CH3)3), 30.65, 30.55, 
30.30, 30.15, 26.86, 26.85 (CH2NHCO, 4 x CH2), 26.81 
(OCH2C(CH3)3), 26.75, 23.69 (CH2), 20.90 (d, 3JC-P = 5.8 Hz, 
CHCH3), 20.70 (d, 3JC-P = 7.6 Hz, CHCH3), 14.48 (CH3).31P 
NMR (202 MHz, MeOH-d4): P 4.34, 4.07. MS (ES+) m/z: 777 
(M+Na+, 100%). Reverse-phase HPLC, eluting with H2O/CH3CN 
from 90/10 to 0/100 in 30 min, Flow = 1mL/min,  = 280 nm, 
tR= 22.51, 22.68 min. 
 
4.1.3.4 N-{3-[5-(2’-Deoxy-5’-O-(1-naphthyl(benzyloxy-L-
alaninyl)phosphate-uridine))] prop-2-ynyl)octanamide (7d). 
Prepared according to standard procedure from nucleoside 2 
(0.30 g, 0.75 mmol) and naphthyl(benzyloxy-L-
alaninyl)phosphorochloridate 6d (0.91 g, 2.25 mmol) in 
anhydrous THF (25 mL) and anhydrous NMI (0.30 mL, 3.80 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
from 98/2 to 95/5. The residue was further purified by 
preparative TLC eluting with CH2Cl2/MeOH  95/5 to give 7d as a 
white solid (14%, 0.08 g). 1H-NMR (500 MHz; MeOD-d4) δH 
8.19-8.17 (m, 1H, Naph), 7.93-7.90 (m, 2H, Naph, H-6), 7.74-
7.69 (m, 1H, Naph), 7.58-7.52 (m, 3H, Naph), 7.40-7.30 (m, 6H, 
Naph, Ph), 6.13-6.10 (m, 1H, H-1’), 5.18-5.10 (m, 2H, 
COOCH2Ph), 4.39-4.32 (m, 1H, H-5’), 4.31- 4.25 (m, 2H, H-3’, 
H-5’), 4.18-4.07 (m, 2H, H-4’, CHCH3), 3.92 (s, 2H, 
NHCH2C≡), 2.19-2.09 (m, 3H, H-2’, COCH2CH2), 1.80-1.75 (m, 
1H, H-2’), 1.59-1.50 (m, 2H, COCH2CH2), 1.40 (d, J = 7.0 Hz, 
3H, CHCH3), 1.36-1.21 (m, 8H, 4 x CH2), 0.89-0.87 (m, 3H, 
CH3). 13C-NMR (125 MHz; MeOH-d4): δC 175.23 (NHCO), 
174.57 (COOCH2Ph), 164.32 (C-4), 150.87 (C-2), 148.60 (d, 2JC-
P = 7.3 Hz, C-1 ‘ipso’ Naph), 144.57, 144.52 (C-6), 137.14, 
136.29 (‘ipso’ OCH2Ph), 129.80, 129.74, 129.64, 129.61, 129.42, 
129.37, 128.97, 127.91, 127.72, 127.62, 126.64, 126.55, 126.27, 
126.18, 122.74, 122.65 (C-3 Naph, C-4 Naph, C-4a Naph, C-5 
Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph, COOCH2Ph), 
116.43 (d, 3JC-P = 2.5 Hz, C-2 Naph), 100.26 (C-5), 90.40 
(CH2C≡C), 87.32, 87.19 (C-1’), 86.91 (d, 3JC-P = 8.8 Hz, C-4’), 
75.43 (CH2C≡C), 72.25, 72.07 (C-3’), 68.14, 68.11 (CH2OPh), 
67.87 (d, 2JC-P = 5.0 Hz, C-5’), 52.00, 51.85 (CHCH3), 41.33, 
41.29 (C-2’), 36.90 (COCH2), 32.86, 30.56, 30.48, 30.25, 30.11, 
26.83, 23.66 (CH2NHCO,  6 x CH2), 20.55 (d, 3JC-P = 6.25 Hz, 
CHCH3), 14.48, 14.41 (CH3). 31P NMR (202 MHz, MeOD-d4): δP 4.36, 3.98. MS (ES+) m/z: 797 (M+Na+, 100%). Reverse 
HPLC, eluting with H2O/ CH3CN from 90/10 to 0/100 in 30 
minutes, Flow = 1 mL/min,  = 280 nm, tR = 16.63 min.  
 
4.1.3.5 N-{3-[5-(2’-Deoxy-5’-O-(phenyl(methoxy-L-
alaninyl)phosphate-uridine))]prop-2-ynyl)octanamide (7e). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and phenyl(methoxy-L-
alaninyl)phosphorochloridate 6e (0.68 g, 2.45 mmol) in 
anhydrous THF (18 mL) and with NMI (0.19 mL, 2.45 mmol). 
The crude compound was purified by flash chromatography on 
silica gel gradient elution of CH2Cl2/MeOH from 98/2 to 94/6 to 
give 7e as a white solid (16%, 0.05 g). 1H NMR (500 MHz, 
MeOH-d4) H 7.99, 7.96 (2s, 1H, H-6), 7.40-7.36 (m, 2H, Ph), 
7.30-7.27 (m, 2H, Ph), 7.23-7.20 (m, 1H, Ph), 6.25-6.20 (m, 1H, 
H-1’), 4.44-4.41 (m, 1H, H-3’), 4.39-4.37 (m, 1H, H-5’), 4.34-
4.31 (m, 1H, H-5’), 4.15-4.12 (m, 1H, H-4’), 4.09 (s, 1H, 
NHCH2), 4.06-4.01 (m, 2H, CHCH3, NHCH2), 3.71, 3.69 (2s, 
3H, COOCH3), 2.34 (ddd, J = 13.7 Hz, J = 6.0 Hz, J = 3.1 Hz, 
0.5H of one diastereoisomer), H-2’, 2.27 (ddd, J = 13.7 Hz, J = 
6.0 Hz, J = 2.9 Hz, 0.5H of one diastereoisomer, H-2’), 2.19-2.15 
(m, 2H, COCH2-), 2.14-2.08 (m, 0.5H of one diastereoisomer, H-2’), 2.01-1.95 (m, 0.5H of one diastereoisomer, H-2’), 1.60-1.56 
(m, 2H, COCH2CH2-), 1.38 (d, J = 7.1 Hz, 3H, CHCH3), 1.34-
1.25 (m, 8H, 4 x CH2), 0.91 (t, J = 6.9 Hz, 3H, -CH2CH3). 13C-
NMR (125 MHz, MeOH-d4): C 175.75, 175.55, 175.27, 175.23 
(COOCH3, CONH), 164.43 (C-4), 152.15 (C-2), 151.03 (‘ipso’ 
Ph), 144.72, 144.68 (C-6), 130.91, 130.89, 126.38, 126.32, 
121.53, 121.49 (PhO), 100.23 (C-5), 90.46, 90.42 (CH2CC), 
87.47, 87.26 (C-1’), 87.13 (d, 3JC-P = 8.1 Hz, C-4’), 87.13 (d, 3JC-P 
= 8.3 Hz, C-4’), 75.42, 75.37 (CH2CC), 72.23, 72.14 (C-3’), 
67.69 (d, 2JC–P = 5.5 Hz, C-5’), 67.57 (d, 2JC–P = 5.3 Hz, C-5’), 
51.70, 51.53 (COOCH3), 50.22 (CHCH3), 41.38, 41.32 (C-2’), 
36.92 (COCH2), 32.89, 30.56, 30.53, 30.27, 30.13, 26.85, 23.67 
(NHCH2CO, 6 x CH2), 20.62 (d, 3JC–P = 6.0 Hz, CHCH3), 20.44 
(d, 3JC–P = 7.1 Hz, CHCH3), 14.43 (CH3). 31P NMR (202 MHz, 
MeOH-d4): P 3.98, 3.57. MS (EI) m/z: 671 (M+Na+, 100%). 
Reverse HPLC, eluting with H2O/CH3CN from 100/0 to 0/100 in 
30 min, Flow = 1 mL/min,  = 254 nm, tR = 18.29 min. 
 
4.1.3.6 N-{3-[5-(2’-Deoxy-5’-O-(phenyl(ethoxy-L-
alaninyl)phosphate-uridine))]prop-2-ynyl)octanamide (7f). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and phenyl(ethoxy-L-
alaninyl)phosphorochloridate 6f (0.71 g, 2.45 mmol) in 
anhydrous THF (15 mL) and anhydrous NMI (0.19 mL, 2.45 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
= 98/2 to 94/6 to give 7f as a white solid (29%, 0.09 g).  1H NMR 
(500 MHz, MeOH-d4) H 7.99, 7.96 (2s, 1H, H-6), 7.40-7.36 (m, 
2H, Ph), 7.30-7.27 (m, 2H, Ph), 7.22-7.19 (m, 1H, Ph), 6.25-6.20 
(m, 1H, H-1’), 4.44-4.41 (m, 1H, H-3’), 4.39-4.37 (m, 1H, H-5’), 
4.35-4.30 (m, 1H, H-5’), 4.20-4.12 (m, 3H, H-4’, COOCH2CH3), 
4.10, 4.05 (2s, 2H, NHCH2), 4.04-3.97 (m, 1H, CHCH3), 2.34 
(m, J = 13.7 Hz, J = 6.0 Hz, J = 3.1 Hz, 0.5H of one 
diastereoisomer, H-2’), 2.27 (m, J = 13.8 Hz, J = 6.0 Hz, J = 3.0 
Hz, 0.5H of one diastereoisomer, H-2’), 2.19-2.15 (m, 2H, 
COCH2-), 2.13-2.07 (m, 0.5H of one diastereoisomer, H-2’), 
1.99-1.94 (m, 0.5H of one diastereoisomer, H-2’), 1.62-1.56 (m, 
2H, COCH2CH2-), 1.38 (d, J = 7.2 Hz, 3H, CHCH3), 1.34-1.24 
(m, 11H, 4xCH2, COOCH2CH3), 0.90 (t, J = 6.9 Hz, 3H, -
CH2CH3). 13C-NMR (125 MHz, MeOH-d4): C 175.76, 175.11, 
175.07 (COOCH2CH3, CONH), 164.39 (C-4), 152.20, 152.14 (C-2), 151.02 (‘ipso’ Ph), 144.71, 144.67 (C-6), 130.92, 130.90, 
126.40, 126.33, 121.53, 121.50 (PhO), 100.28 (C-5), 90.48, 
90.45 (CH2CC), 87.43, 87.24 (C-1’), 87.12 (d, 3JC-P = 8.3 Hz, C-4’), 86.94 (d, 3JC-P = 8.2 Hz, C-4’), 75.47, 75.43 (CH2CC), 
72.21, 72.12 (C-3’), 67.71 (d, 2JC–P = 5.5 Hz, C-5’), 67.59 (d, 2JC–
P = 5.4 Hz, C-5’), 62.52, 62.51 (COOCH2CH3), 51.81, 51.63 
(CHCH3), 41.42, 41.37 (C-2’), 36.96 (COCH2), 32.90, 30.63, 
30.59, 30.30, 30.15, 26.87, 23.69 (NHCH2CO, 6 x CH2), 20.74 
(d, 3JC–P = 6.2 Hz, CHCH3), 20.55 (d, 3JC–P = 7.1 Hz, CHCH3), 
14.57, 14.55, 14.47 (COOCH2CH3, CH3). 31P NMR (202 MHz, 
MeOH-d4): P 3.99, 3.58. MS (EI) m/z: 685 (M+Na+, 100%). 
Reverse HPLC, eluting with H2O/ CH3CN from 100/0 to 0/100 in 
30 min, Flow = 1 mL/min,  = 254 nm, tR = 19.10 min. 
 
4.1.3.7 N-{3-[5-(2’-Deoxy-5’-O-(phenyl(propyloxy-L-
alaninyl)phosphate-uridine))] prop-2-ynyl)octanamide (7g). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and phenyl(propyloxy-L-
alaninyl)phosphorochloridate 6g (0.71 g, 2.45 mmol) in 
anhydrous THF (15 mL) and anhydrous NMI (0.19 mL, 2.45 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
from 98/2 to 94/6 to give 7g as a white solid. 1H NMR  (500 
MHz, MeOH-d4): δH 7.99, 7.97 ( 2s, 1H, CH-6), 7.40-7.35 (m, 
2H, Ph), 7.31-7.26 (m, 2H, Ph), 7.23-7.19 (m, 1H, Ph), 6.24-6.19 
(m, 1H, H-1’), 4.39-4.35 (m, 1H, H-3’), 4.34-4.20 (m, 2H, H-5’), 
4.15-3.99 (m, 6H, H-4’, OCH2, NHCH2C≡C, CHCH3), 2.34 (ddd, 
J = 14.0, 6.0 and 3.0 Hz, 0.5H of one diastereoisomer, H-2’), 
2.25 (ddd, J = 13.5, 6.0 and 2.5Hz, 0.5H of one diastereoisomer, 
H-2’), 2.19-2.14 (m, 2H, H-2’, COCH2CH2), 2.12-2.00 (m, 1H of 
one diastereoisomer, H-2’), 199-1.96 (m, 1H of one 
diastereoisomer, H-2’), 1.70-1.63 (m, 2H, OCH2CH2), 1.62-1.56 
(m, 2H, COCH2CH2), 1.41-1.37 (d, J = 7.5 Hz, 3H, CHCH3), 
1.34-1.26 (m, 8H, 4 x CH2), 0.96, 0.95 (2t J = 7.5 Hz, 3H, 
OCH2CH3), 0.90 (t, J = 7.0 Hz, 3H, CH3). 13C NMR (125 MHz, 
MeOH-d4): δC 175.75, 175.72 (CONH), 175.16 (d, 3JC-P = 4.5 Hz, 
CO2CH2), 174.88 (d, J = 5.4 Hz, CO2CH2), 164.40, 164.42 (C-4), 
152.19 (d, 2JC-P = 7.1Hz ‘ipso’ PhO), 152.19 (d, 2JC-P = 7.1 Hz 
‘ipso’ PhO), 152.13 (d, 2JC-P = 6.5Hz ‘ipso’ PhO), 151.04 (C-2), 
144.70, 144.74, (C-6), 130.89, 130.87, 126.36, 126.29, (PhO), 
121.52 (d, 2JC-P = 7.1 Hz, PhO), 100.25, 100.28 (C-5), 90.46, 
90.44 (CH2C≡C), 87.48, 87.37 (C-1’), 86.97 (d, 3JC-P = 8.2 Hz, 
C-4’), 86.16 (d, 3JC-P= 8.1 Hz, C-4’), 75.41, 75.34 (CH2C≡C), 
72.21, 72.12 (C-3’), 68.06, 68.05 (OCH2), 67.75 (d, 2JC-P = 5.6 
Hz, C-5’), 67.63 (d, 2JC-P = 5.5 Hz, C-5’), 51.88, 51.72 (CHCO2), 
41.38, 41.35 (C-2’), 36.96 (COCH2), 32.90, 30.59, 30.56, 30.27, 
30.09, 26.87, 23.05, 23.03 (-CH2-), 20.58 (d, 3JC-P = 7.0 Hz, 
CHCH3), 20.77 (d, 3JC-P = 6.1 Hz, CHCH3), 14.37 (CH3), 10.64 
(OCH2CH3); 31P NMR (202 MHz, MeOH-d4): P 4.00, 3.59. MS 
(EI) m/z: 711 (M+Cl-, 100%). Reverse-phase HPLC, eluting with 
H2O/CH3CN from 90/10 to 0/100 in 35 min, Flow = 1 mL/min,  
= 280 nm, tR= 17.77 min. 
 
4.1.3.8 N-{3-[5-(2’-Deoxy-5’-O-(phenyl-(benzyloxy-L-
alaninyl)phosphate-uridine))]prop-2-ynyl)octanamide (7h). 
Prepared according to standard procedure nucleoside 2 (0.30 g, 
0.75 mmol) and phenyl(benzyloxy-L-
alaninyl)phosphorochloridate 6h (0.80 g, 2.25 mmol) in 
anhydrous THF (25 mL) and anhydrous NMI (0.30 mL, 3.80 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
= 98/2 to 95/5. The residue was further purified by preparative 
TLC, eluting with CH2Cl2/MeOH 95/5 to give 7h as a white solid 
(11%, 0.06 g). 1H-NMR (500 MHz; MeOH-d4) δH 7.97-7.93 (m, 
1H, H-6), 7.91-7.87 (m, 1H, Ph), 7.41-7.32 (m, 6H, Ph), 7.29-
7.17 (m, 3H, Ph), 6.23-6.17 (m, 1H, H-1’), 5.20-5.11 (m, 2H, 
OCH2Ph), 4.41-4.34 (m, 1H, H-3’), 4.33-4.29 (m, 2H, H-5’), 
4.11-4.01 (m, 2H, H-4’, CHCH3), 3.31 (s, 2H, NHCH2C≡), 2.32-
2.21 (m, 3H, H-2’, COCH2CH2), 1.93-1.88 (m, 1H, H-2’), 1.63-
1.51 (m, 2H, COCH2CH2), 1.41 (d, J = 7.0 Hz, 3H, CHCH3), 
1.37-1.21 (m, 8H, 4 x CH2), 0.92-0.88 (m, 3H, CH3). 13C-NMR 
(125 MHz; MeOD-d4): δC 174.93 (NHCO), 171.69 (CO2CH2Ph), 
164.37 (C-4), 152.25 (d, 3JC-P = 7.4 Hz ‘ipso’ OPh), 151.17 (C-2), 
144.84, 144.70 (C-6), 137.21, 137.18 (‘ipso’ OCH2Ph), 131.25, 
130.90, 129.80, 129.76, 129.73, 129.65, 129.64, 129.61, 129.44, 
129.40, 129.38, 129.18, 126.99, 126.39, 126.30, 121.55, 121.52, 
121.47 (Ph, OCH2Ph), 100.22 (C-5), 90.50 (CH2C≡C), 87.36, 
87.32 (C-1’), 87.14, 87.07 (d, 3JC-P = 8.8 Hz, C-4’), 75.42 
(CH2C≡C), 72.24, 72.06 (C-3’), 68.13, 68.09 (PhCH2), 67.65 (d, 
2JC-P = 5.8 Hz, C-5’), 51.89, 51.69 (CHCH3), 41.37, 40.99 (C-2’), 
36.99, 36.93 (COCH2), 32.89, 30.58, 30.54, 30.45, 30.28, 26.85, 
23.67 (NHCH2CO, 6 x CH2), 20.61, 20.56 (CHCH3), 14.43 
(CH3). 31P NMR (202 MHz, MeOH-d4): δP 4.01, 3.51. MS (ES+) 
m/z: 747 (M+Na+, 100%). Reverse HPLC, eluting with 
H2O/CH3CN from 90/10 to 0/100 in 30 minutes, Flow = 1 
mL/min,  = 280 nm, tR = 16.22 min. 
 
4.1.3.9 N-{3-[5-(2’-Deoxy-5’-O-(phenyl(benzyloxy-D-
alaninyl)phosphate-uridine))] prop-2-ynyl)octanamide (7i). 
Prepared according to standard procedure from nucleoside 2 
(0.25 g, 0.61 mmol) and phenyl(benzyloxy-D-
alaninyl)phosphorochloridate 6i (1.10 g, 3.05 mmol) in 
anhydrous THF (20 mL) and anhydrous  NMI (0.24 mL, 3.05 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of ethyl 
acetate/MeOH from 100/0 to 98/2. The residue was further 
purified by preparative TLC eluting with CH2Cl2/MeOH 90/10 to 
give 7i as a white solid (16%, 0.07 g). 1H NMR (500 MHz; 
MeOH-d4): H 7.99, 7.82 (2s, 1H, H-6), 7.38-7.20 (m, 10H, PhO, 
COOCH2Ph), 6.21 (dd, J = 7.4 and 6.1 Hz, 0.5H of one 
diastereoisomer, H-1’), 6.16 (dd, J = 7.4 Hz and 6.1 Hz, 0.5H of 
one diastereoisomer, H-1’), 5.15 (2H, m, OCH2Ph), 4.41-4.25 (m, 
3H, H-3’, H-5’), 4.16-4.01 (m, 4H, H-4’, NHCH2C≡C, CHCH3), 
2.29 (ddd, J = 13.7 Hz, J = 6.0 Hz, J = 3.0 Hz, 0.5H of one 
diastereoisomer, H-2’), 2.18-2.06 (m, 3H, H-2’, COCH2CH2), 
1.70 (m, 0.5H of one diastereoisomer, H-2’), 1.60-1.57 (m, 2H, 
COCH2CH2), 1.43 (d J = 7.1 Hz, 1.5H of one diastereoisomer, 
CHCH3), 1.36 (d, J = 7.1 Hz, 1.5H of one diastereoisomer, 
CHCH3), 1.35-1.26 (m, 8H, 4 x CH2), 0.90 (t, 3H, J = 7.0 Hz, 
CH3). 13C NMR (125 MHz; MeOH-d4): C 175.69 (CH2CO), 
174.87 (d, 3JC-P = 3.9 Hz, COOCH2Ph), 174.80 (d, 3JC-P = 4.3 Hz, 
COOCH2Ph), 164.37 (C-4), 152.20 (d, 2JC-P = 6.6 Hz, ‘ipso’ 
PhO), 152.01 (d, 2JC-P = 6.7 Hz, ‘ipso’ PhO), 150.85 (C-2), 
144.79, 144.41 (C-6), 137.18, 137.04 (‘ipso’ COOCH2Ph), 
130.93, 130.83, 129.59, 129.56, 129.46, 129.41, 129.37, 129.35, 
126.33, 121.60, 121.56, 121.27, 121.23 (PhO, COOCH2Ph), 
100.21, 100.12, (C-5), 90.78, 90.26 (CH2C≡C), 87.24, 86.94 (C-1’), 87.05 (d, 3JC-P = 8.6 Hz, C-4’), 86.90 (d, 3JC-P = 8.7 Hz, C-4’), 75.48, 75.44 (CH2C≡C), 72.14, 72.03 (C-3’), 68.13, 68.07 
(OCH2Ph), 67.70 (d, 2JC-P = 5.5 Hz, C-5’), 67.10 (d, 2JC-P = 4.8 
Hz, C-5’), 51.77, 51.56 (CHCH3), 41.36 (C-2’), 36.90 (CH2CO), 
32.85, 30.56, 30.47, 30.25, 30.10, 26.82, 23.65 (CH2NHCO, 6 x 
CH2), 20.43 (d, 3JC-P = 6.8 Hz, CHCH3), 20.39 (d, 3JC-P = 7.6 Hz, 
CHCH3), 14.39 (CH3). 31P NMR (202 MHz; MeOH-d4): δP 3.98, 
3.50. MS (ES+) m/z: 747 (M+Na+, 100%). Reverse-phase HPLC, 
eluting with H2O/ACN from 90/10 to 0/100 in 20 min, Flow = 1 
mL/min,  = 280 nm, tR= 14.48 min, 14.86 min. 
 
4.1.3.10 N-{3-[5-(2’-Deoxy-5’-O-(phenyl(benzyloxy-
glycinyl)phosphate-uridine))]prop-2-ynyl)octanamide (7j). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and phenyl(benzyloxy-
glycinyl)phosphorochloridate 6j (0.87 g, 2.45 mmol) in 
anhydrous THF (20 mL) and anhydrous NMI (0.19 mL, 2.45 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
from 98/2 to 95/5 to give 7j as a white solid (29%, 0.10 g). 1H 
NMR (500 MHz, MeOH-d4): H 8.09, 7.89 (2s, 1H, H-6), 7.38-
7.19 (m, 10H, Ph, OCH2Ph), 6.24-6.18 (m, 1H, H-1’), 5.23-5.13 
(m, 2H, OCH2Ph), 4.36-4.30 (m, 3H, H-3’, H-5’), 4.13-4.08 (m, 
1H, H-4’), 4.08, 4.07, 4.02 (3s, 2H, NHCH2C≡C), 3.91-3.85 (m, 
2H, CH2CO2Bn), 2.30 (ddd J = 14.0, 6.5 and 3.5 Hz, 0.5H of one 
diastereoisomer, H-2’), 2.18-2.09 (m, 3H, H-2’, COCH2CH2), 
1.80-1.74 (m, 0.5H of one diastereoisomer, H-2’), 1.59-1.55 (m, 
2H, COCH2CH2), 1.30-1.27 (m, 8H, 4 x CH2), 0.91-0.86 (t, J = 
6.7 Hz, 3H, CH3). 13C-NMR (125 MHz, MeOH-d4): C 175.79, 
175.77 (CONH), 172.42, 172.38 (d, 3JC-P= 4.0 Hz, COOBn), 
164.38 (C-4), 152.20 (d 2JC-P = 7.0 Hz, ‘ipso’ PhO), 151.04, 
150.97 (C-2), 144.84, 144.60 (C-6), 137.10, 137.14 (‘ipso’ 
OCH2Ph), 130.97, 130.90, 129.63, 129.60, 129.50, 129.44, 
126.43, 126.37 (PhO, OCH2Ph), 121.55 (d, 3JC-P = 4.5 Hz, PhO), 
121.37 (d, 3JC-P = 4.6 Hz, PhO), 100.20, 100.17 (C-5), 90.78, 
90.44 (C≡C), 87.32 (C-1’), 87.20 (d, 3JC-P = 8.2 Hz, C-4’) 87.10 
(C-1’), 87.03 (d, 3JC-P = 8.2 Hz, C-4’), 75.41, 75.34 (CH2C≡C), 
72.28, 72.20 (C-3’), 68.08 (OCH2Ph) 67.79 (d, 2JC-P = 5.7 Hz, C-5’), 67.49 (d, 2JC-P = 5.1 Hz, C-5’), 44.03, 43.96 (CH2CO2), 
41.43, 41.40 (C-2’), 36.94 (COCH2), 32.89, 32.88, 30.53, 30.48, 
30.29, 30.14, 26.85, 23.68 (CH2NHCO, 6 x CH2), 14.43 
(CH3).31P NMR (202 MHz, MeOH-d4): P 5.02, 4.93. MS (ES+) 
m/z: 733 (M+Na+, 100%). Reverse-phase HPLC, eluting with 
H2O/CH3CN from 90/10 to 0/100 in 30 min, Flow = 1mL/min,  
= 280 nm, tR= 18.78, 19.15 min. 
 
4.1.3.11 N-{3-[5-(2’-Deoxy-5’-O-(phenyl(benzyloxy- 
dimethylglycine)phosphate-uridine))] prop-2-ynyl) octanamide 
(7k). Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and phenyl(benzyloxy-L-
dimethylglycine)phosphorochloridate 6k (0.86 g, 2.45 mmol) in 
anhydrous THF (15 mL) and anhydrous NMI (0.19 mL, 2.45 
mmol). The crude compound was purified by flash 
chromatography on silica gel gradient elution of CH2Cl2/MeOH 
from 98/2 to 94/6 to give 7k as a white solid. 1H NMR  (500 
MHz, MeOH-d4): δH 7.95 (s, 0.3H of one diastereoisomer, H-6), 
7.86 (s, 0.7H of one diastereoisomer, H-6), 7.40 - 7.17 (m, 10H, 
Ph, OCH2Ph), 6.21-6.15 (m, 1H, H-1’), 5.20 – 5.12 (m, 
2H,OCH2Ph), 4.32-4.21( m, 3H, H-3’, H-5’), 4.09- 3.99 (m, 3H, 
H-4’, NHCH2C≡), 2.32-2.24 (m, 0.7H of one diastereoisomer, H-2’), 2.20-2.15 (m, 2.3H, H-2’, one diastereoisomer, NHCOCH2), 
2.13-2.05 (m, 0.70H, H-2’), 1.77-1.72 (m, 0.30H of one 
diastereoisomer, H-2’), 1.61-1.48 (m, 6H, NHCOCH2CH2, 
C(CH3)2), 1.36-1.23 (m, 8H, 4 x CH2), 0.95–0.85 (t, J = 6.0Hz, 
3H, CH2CH3). 13C NMR (125 MHz, MeOH-d4): δc 176.75 (d, 3JC-
P = 2.5 Hz, COCH2), 176.55, 176.53 (CONH), 164.52 (C-4), 
152.35 (d, 2JC-P = 6.9Hz ‘ipso’ PhO), 152.22 (d, 2JC-P = 6.8 Hz ‘ipso’ PhO), 151.11 (C-2), 144.86, 144.62 (C-6), 137.32 (‘ipso’ 
OCH2Ph), 130.90, 130.81, 129.63, 129.54, 129.35, 129.30, 
129.20, 126.31, 126.22 (PhO, OCH2Ph), 121.70 (d, 3JC-P = 5.0 
Hz, PhO), 121.56 (d, 3JC-P = 4.6 Hz, PhO), 90.75, 90.60 
(CH2C≡C), 87.00 (d, 3JC-P = 10.6 Hz, C-4’), 86.79 (d, 3JC-P = 10.6 
Hz, C-4’), 86.26 (C-1’), 75.49, 75.38 (CH2C≡C), 72.07, 71.99 
(C-3’), 68.36, 68.35 (OCH2), 67.76 (d, 2JC-P = 5.62 Hz, C-5’), 
67.53 (d, 2JC-P = 5.78 Hz, C-5’), 41.27, 41.24 (C-2’), 36.99 
(NHCOCH2), 32.92, 30.61, 30.59, 30.17, 30.12 (CH2), 27.93 (d, 
3JC-P = 6.4 Hz, CH3), 27.85 (d, 3JC-P = 6.4 Hz, CH3), 27.67 (d, 3JC-
P = 4.2 Hz, CH3), 27.57 (d, 3JC-P = 4.2 Hz, CH3), 23.71, 23.69, 
26.90 (CH2), 14.37 (CH2CH3); 31P NMR (202 MHz, MeOH-d4): P 2.39, 2.1. MS (EI) m/z: 773 (M+Cl-, 100%). Reverse-phase 
HPLC, eluting with H2O/ CH3CN from 90/10 to 0/100 in 35 min, 
Flow = 1 mL/min,  = 280 nm, tR= 19.24 min. 
 
4.1.3.12 N-{3-[5-(2’-Deoxy-5’-O-(phenyl(benzyloxy-L-
valinyl)phosphate-uridine))]prop-2-ynyl)octanamide (7l). 
Prepared according to standard procedure from nucleoside 2 
(0.20 g, 0.49 mmol) and phenyl(benzyloxy-L-
valinyl)phosphorochloridate 6l (0.93 g, 2.45 mmol) in anhydrous 
THF (20 mL) and anhydrous NMI (0.19 mL, 2.45 mmol). The 
crude compound was purified by flash chromatography on silica 
gel gradient elution of CH2Cl2/MeOH from 98/2 to 95/5. The 
residue was further purified by preparative TLC, eluting with 
CH2Cl2/MeOH 95/5 to give 7l as a white solid (14%, 0.05 g). 1H 
NMR (500 MHz, MeOH-d4): H 7.95 (s, 0.35H of one 
diastereoisomer, H-6), 7.91 (s, 0.65H of one diastereoisomer, H-
6), 7.40-7.18 (m, 10H, Ph, OCH2Ph), 6.21-6.17 (m, 1H, H-1’), 
5.21-5.09 (m, 2H, OCH2Ph), 4.39-4.37 (m, 1H, H-3’), 4.34-4.22 
(m, 2H, H-5’), 4.11-4.06 (m, 3H, H-4’, NHCH2C≡), 3.81 (dd, J = 
9.5, 5.5 Hz, 0.65H of one diastereoisomer, CHCH(CH3)2), 3.76 
(dd, J = 10.0, 6.0 Hz, 0.35H of one diastereoisomer, 
CHCH(CH3)2)), 2.30 (ddd, J = 13.5, 6.5 and 3.0 Hz, 0.35H of one 
diastereoisomer, H-2’), 2.22 (ddd, J = 13.5, 6.0 and 3.0 Hz, 
0.65H of one diastereoisomer, H-2’), 2.18-2.04 (m, 3.35H, H-2’ 
of one diastereoisomer, COCH2CH2,  CH(CH3)2), 1.90-1.64 (m, 
0.65H of one diastereoisomer, H-2’), 1.61-1.65 (m, 2H, 
COCH2CH2), 1.33-1.29 (m, 8H, 4 x CH2), 0.92-0.86 (m, 9H, -
CH2CH3, CH(CH3)2). 13C NMR (125 MHz, MeOH-d4): C 
175.72, 175.69 (CONH), 174.09 (d, 3JC-P= 2.7 Hz, CO2Bn), 
173.77 (d, 3JC-P= 3.7 Hz, CO2Bn), 164.46 (C-4), 152.25 (d, 2JC-P = 
7.2 Hz, ‘ipso’ PhO), 150.99 (C-2), 144.71, 144.68 (C-6), 137.20, 
137.13 (‘ipso’ OCH2Ph), 130.91, 130.87, 129.73, 129.67, 129.65, 
129.51, 126.44, 126.29 (Ph, OCH2Ph), 121.68 (d, 3JC-P = 4.5 Hz, 
PhO), 121.52 (d, 3JC-P = 5.5 Hz, PhO), 100.28, 100.26 (C-5), 
90.54, 90.51 (C≡C), 87.42 87.27 (C-1’), 87.15, 86.85 (d, 3JC-P = 
8.1 Hz, C-4’), 75.59, 75.53 (CH2C≡C), 72.28, 72.04 (C-3’), 
68.04, 67.96 (OCH2Ph) 67.87 (d, 2JC-P = 5.7 Hz, C-5’), 67.65 (d, 
2JC-P = 5.4 Hz, C-5’), 58.38 (CHCH(CH3)2), 41.40, 41.38 (C-2’), 
36.97, 36.96 (CH2CO), 32.91, 30.68, 30.64, 30.32, 30.17, 26.89, 
26.87, 23.70 (CH2NHCO, 6 x CH2), 19.70, 19,64, 18.49, 18,43, 
18.06, 14.46 (CH(CH3)2, CH3).31P NMR (202 MHz, MeOH-d4): P 4.95, 4.30. MS (ES+) m/z: 775 (M+Na+, 100%). Reverse-
phase HPLC, eluting with H2O/CH3CN from 90/10 to 0/100 in 30 
min, Flow = 1 mL/min,  = 280 nm, tR= 21.23, 21.49 min. 
 
4.2. Biological evaluation 
4.2.1 Assay for antimycobacterial activity  
M. tuberculosis H37Rv (ATCC27294) was grown in 
Middlebrook 7H9 broth supplemented with 0.02% (v/v) glycerol, 
0.05% (v/v) tween-80 and 10% oleic acid, albumin, dextrose and 
catalase (OADC; BD Biosciences) as a stand culture at 37C. M. 
bovis BCG (ATCC35734) was grown in Middlebrook 7H9 broth 
supplemented with 0.02% (v/v) glycerol, 0.05% (v/v) tween-80 
and 10% albumin, dextrose and catalase (ADC; BD Biosciences) 
in a roller bottle at 2 rpm at 37C. The antimycobacterial 
activities of the compounds were tested following the HT-
SPOTi.28,29 The high throughput growth inhibition assay was 
conducted in a semi-automated 96 well plate format as described 
previously.26 Briefly, compounds dissolved in DMSO at a final 
concentration of 250 mg/L were serially diluted and dispensed in 
a volume of 2 µL into each well of a 96 well plate to which 200 
µL of Middlebrook 7H10 agar medium kept at 55C 
supplemented with 0.05% (v/v) glycerol and 10% (v/v) OADC 
was added. A well with no compounds (DMSO only) and 
isoniazid were used as experimental controls. To all the plates, a 
drop (2 µL) of mycobacterial culture containing 2 X 103 colony-
forming units (CFUs) was spotted in the middle of each well and 
the plates were incubated at 37C for up to two weeks. The 
minimum inhibitory concentrations (MICs) were determined as 
the lowest concentrations of the compound investigated where 
mycobacterial growth was completely inhibited by the presence 
of the compound.  
 
4.2.2 Assay for antibacterial activity 
E. coli DH5α (ATCC53868) was grown in Luria-Bertani broth 
(Oxoid, Thermoscientific) at 180 rpm as shaking culture with an 
incubation temperature of 37C. The antibacterial activities of the 
compounds were tested using the HT-SPOTi as mentioned 
earlier, using appropriate culture medium and growth conditions. 
The plates were incubated overnight following which 
observations were recorded.  
 
4.2.3 Assay for antiviral activity  
Cells. Human embryonic lung (HEL) fibroblasts were grown 
in minimum essential medium (MEM) supplemented with 10% 
inactivated fetal calf serum (FCS), 2 mM L-glutamine, and 0.3% 
sodium bicarbonate. 
Viruses. The laboratory wild-type varicella zoster virus (VZV) 
strain Oka, the thymidine kinase-deficient VZV strain 07-1, 
herpes simplex virus (HSV-1, KOS), (HSV-2, G), the thymidine 
kinase-deficient (ACVR) HSV-1 strain B-2006, human 
cytomegalovirus (HCMV) strains Davis and AD-169, and 
vaccinia virus (VV) were used in the virus inhibition assays. 
 
Confluent HEL cell cultures grown in 96-well microtiter 
plates were inoculated with VZV at an input of 20 plaque 
forming units (PFU) per well or with HCMV at an input of 100 
PFU per well. Confluent HEL cell cultures were inoculated with 
HSV at 100 CCID50 (50% cell culture infective dose) per well. 
After a 1-2 h incubation period, residual virus was removed and 
the infected cells were further incubated with MEM 
(supplemented with 2% inactivated FCS, 2 mM L-glutamine, and 
0.3% sodium bicarbonate) containing varying concentrations of 
the compounds. Antiviral activity was expressed as EC50 (50% 
effective concentration), or compound concentration required to 
reduce viral plaque formation after 5 days (varicella zoster virus 
(VZV)) or virus-induced cytopathicity (HCMV after 7 days and 
HSV, VV after 3 days) by 50% compared to the untreated 
control. 
4.2.4 Assay for eukaryotic cell toxicity Confluent monolayers 
of HEL cells as well as growing HEL cells in 96-well microtiter 
plates were treated with different concentrations of the 
experimental drugs. Cell cultures were incubated for 3 (growing 
cells) or 5 (confluent cells) days. At the indicated time, the cells 
were trypsinized, and the cell number was determined using a 
Coulter counter (Beckman, Analis, Suarlée, Belgium). The 50% 
cytostatic concentration (CC50) was defined as the compound 
concentration required to reduce the cell number by 50%. 
Acknowledgments 
We acknowledge TBD-UK (www.tbd-uk.org.uk) for 
facilitating interdisciplinary collaboration. 
Funding 
The research of JB, GA and RS was supported by the KU 
Leuven (GOA 10/14) and SB was funded by the Medical 
Research Council, UK (New Investigators Research Grant: 
G0801956 and TBD-UK Collaboration Grant: G0802079). 
 
References and notes 
1. Smith, K.C.; Armitige, L.; Wanger, A. A review of tuberculosis: 
reflections on the past, present and future of a global epidemic 
disease. Expert. Rev. Anti. Infect. Ther. 2003, 1, 483-91. 
2. Glickman, M.S.; Jacobs, W.R. Jr Microbial pathogenesis of 
Mycobacterium tuberculosis: dawn of a discipline. Cell 2001, 104, 
477-85. 
3. World Health Organisation. Global Tuberculosis Report 2013. 
London: 2013. 
http://www.who.int/tb/publications/global_report/en/ (3 June 
2013, date last accessed). 
4. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The 
challenge of new drug discovery for tuberculosis. Nature 2011, 
469, 483-90. 
5. Myllykallio, H.; Lipowski, G.; Leduc, D.; Filee, J.; Forterre, P.; 
Liebl, U. et al. An alternative flavin-dependent mechanism for 
thymidylate synthesis. Science 2002, 297, 105-7.  
6. Hunter, J.H.; Gujjar, R.; Pang, C.K.; Rathod, P.K.; Kinetics and 
ligand-binding preferences of Mycobacterium tuberculosis 
thymidylate synthases, ThyA and ThyX. PLoS One 2008, 3, 
e2237. 
7. Koehn, E. M.; Fleischmann, T.; Conrad, J. A., Palfey, B. A., 
Lesley, S. A., Mathews I.I.; Kohen, A. An unusual mechanism of 
thymidylate biosynthesis in organisms containing the thyX gene. 
Nature 2009, 458, 919-23.  
8. Griffin, J. E.; Gawronski, J. D.; Dejesus, M. A.; Ioerger, T. R.; 
Akerley, B. J.; Sassetti C. M. High-resolution phenotypic profiling 
defines genes essential for mycobacterial growth and cholesterol 
catabolism. PLoS Pathog 2011, 7, e1002251. 
9. Fivian-Hughes, A.S.; Houghton, J.; Davis, E.O. Mycobacterium 
tuberculosis thymidylate synthase gene thyX is essential and 
potentially bifunctional, while thyA deletion confers resistance to 
p-aminosalicylic acid. Microbiology 2012, 158, 308-18. 
10. Basta, T.; Boum, Y.; Briffotaux, J.; Becker, H. F.; Lamarre-
Jouenne, I.; Lambry, J. C.; Skouloubris, S.; Liebl, U.; Graille, M.; 
van Tilbeurgh, H.; Myllykallio, H. Mechanistic and structural 
basis for inhibition of thymidylate synthase ThyX. Open Biol 
2012, 2, 120120. 
11. K̈gler, M.; Vanderhoydonck, B.; De Jonghe, S.; Rozenski, J.; 
Van Belle, K.; Herman, J.;. Louat, T.; Parchina, A.; Sibley, C.; 
Lescrinier, E.; Herdewijn, P. Synthesis and Evaluation of 5-
Substituted 2′-deoxyuridine Monophosphate Analogues As 
Inhibitors of Flavin-Dependent Thymidylate Synthase in 
Mycobacterium tuberculosis. J Med Chem 2011, 54, 4847-62. 
12. Niederweis, M. Mycobacterial porins-new channel proteins in 
unique outer membranes. Mol Microbiol 2003, 49, 1167-77. 
13. Louw, G.E.; Warren, R.M; Gey van Pittius, N.C.; McEvoy, 
C.R.E.; Van Helden, P.D.; Victor, T.C. A balancing act: 
efflux/influx in mycobacterial drug resistance. Antimicrob Agents 
Chemother 2009, 53, 3181-9. 
14. Mehellou, Y.; Balzarini, J.; McGuigan, C. Aryloxy 
phosphoramidate triesters: a technology for delivering 
monophosphorylated nucleosides and sugars into cells. 
ChemMedChem 2009, 4, 1779-91. 
15. Hecker, S.J.; Erion, M.D. Prodrugs of phosphates and 
phosphonates. J Med Chem 2008, 51, 2328-45. 
16. McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Brancale, A.; 
Zonta, N.; Chamberlain, S.; Vernachio, J.; Hutchins, J.; Hall, A.; 
Ames, B.; Gorovits, E.; Ganguly, B.; Kolykhalov, A.; Wang, J.; 
Muhammad, J.; Patti, J.M.; Henson, G. Design, synthesis and 
evaluation of a novel double pro-drug: INX-08189. A new clinical 
candidate for hepatitis C virus. Bioorg Med Chem Lett 2010, 20, 
4850-4. 
17. McGuigan, C.; Murziani, P.; Slusarczyk, M.; Gonczy, B.; Vande 
Voorde, J.; Liekens, S.; Balzarini, J. Phosphoramidate ProTides of 
the anticancer agent FUDR successfully deliver the preformed 
bioactive monophosphate in cells and confer advantage over the 
parent nucleoside. J Med Chem 2011, 54, 7247-58. 
18. Serpi, M.; Bibbo, R.; Rat, S.; Roberts, H.; Hughes, C.; Caterson, 
B.; Alcaraz M.J.; Gibert, A.T.; Verson, C.R.; McGuigan, C. Novel 
phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with 
antidegenerative activity on bovine and human cartilage explants. 
J Med Chem 2012, 55, 4629-39. 
19. Derudas, M.; Carta, D.; Brancale, A.; Vanpouille ,C.; Lisco, A.; 
Margolis, L.; Balzarini, J.; McGuigan, C. The application of 
phosphoramidate protide technology to acyclovir confers anti-HIV 
inhibition. J Med Chem 2009, 52, 5520-30. 
20. De Clercq, E. Antiviral and antitumor activities of 5-substituted 2'-
deoxyuridines. Methods Find Exp ClinPharmacol 1980, 2, 253-
67.  
21. Cristofoli, W.A.; Wiebe, L.I.; De Clercq, E.; Andrei, G.; Snoeck, 
R.; Balzarini, J.;  Knaus, E. E. 5-alkynyl analogs of arabinouridine 
and 2'-deoxyuridine: cytostatic activity against herpes simplex 
virus and varicella-zoster thymidine kinase gene-transfected cells. 
J Med Chem 2007, 50, 2851-7. 
22. Brancale, A.; McGuigan, C.; Andrei, G.; Snoeck, R.; De Clercq, 
E.; Balzarini, J. Bicyclic nucleoside inhibitors of Varicella-Zoster 
Virus (VZV): the effect of a terminal halogen substitution in the 
side-chain. Bioorg Med Chem Lett 2000, 10, 1215-7. 
23. Rahim, S.G.; Trevidi, N.; Selway, J.; Darby, G.; Collins, P.; 
Powell, K.L.; et al. 5-Alkynyl Pyrimidine Nucleosides as Potent 
Selective Inhibitors of Varicella-Zoster Virus. Antivir Chem 
Chemother 1992, 3, 293-7. 
24. McGuigan, C.; Pathirana, R.N.; Migliore, M. Adak,  R.; Luoni, 
G.; Jones, A.T.; Díez-Torrubia A, Camarasa MJ, Velázquez S, 
Henson G, Verbeken E, Sienaert R, Naesens L, Snoeck R, Andrei 
G, Balzarini J. Preclinical development of bicyclic nucleoside 
analogues as potent and selective inhibitors of varicella zoster 
virus. J Antimicrob Chemother 2007, 60, 1316-30. 
25. van Boom, J.; Burgers, P.M.J.; Crea, R.; Luyten, W.C.M.M.; 
Vink, A.B.J.; Reese, C.B.. Phosphorylation of nucleoside 
derivatives with aryl phosphoramidochloridates. Tetrahedron 
1975, 31, 2953-9.  
26. Guzman, J.D.; Evangelopoulos, D.; Gupta, A.; Birchall, K.; 
Mwaigwisya, S.; Saxty, B.; McHugh, T.; Gibbons, S.; Malkinson, 
J.; Bhakta, S. Anti-tubercular specific activity of ibuprofen and 
other 2-arylpropanoic acids using the HT-SPOTi whole-cell 
phenotypic assay. BMJ Open 2013, Accepted in press. 
27. De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; 
Maudgal, P.C. A novel selective broad-spectrum anti-DNA virus 
agent. Nature 1986, 323, 464-7. 
28.  Evangelopoulos, D., and Bhakta, S. Rapid methods for testing 
inhibitors of mycobacterial growth. Methods Mol Biol 2010, 642, 
193-201. 
29. Gupta, A.; Bhakta, S. An integrated surrogate model for screening 
of drugs against Mycobacterium tuberculosis. J Antimicrob 
Chemother 2012, 67, 1380-91. 
 
 
 
 
 
